Sugi Predict

Sugi Predict / Targets / CDC37

CDC37

Hsp90 co-chaperone Cdc37 · Q16543 · CDC37 on Sugi Atlas →

1,532 patent compounds predicted against CDC37, 1,371 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4127512 SCHEMBL4127512 1.00 7/20
SCHEMBL4129503 SCHEMBL4129503 1.00 7/20
SCHEMBL4136279 SCHEMBL4136279 0.79 7/20
SCHEMBL4124842 SCHEMBL4124842 0.78 7/20
SCHEMBL12454188 SCHEMBL12454188 0.77 7/20
SCHEMBL4133476 SCHEMBL4133476 0.75 7/20
SCHEMBL4138179 SCHEMBL4138179 0.75 7/20
SCHEMBL4141443 SCHEMBL4141443 0.74 7/20
SCHEMBL4141644 SCHEMBL4141644 0.74 7/20
SCHEMBL4126635 SCHEMBL4126635 0.71 7/20
SCHEMBL12454377 SCHEMBL12454377 0.64 7/20
SCHEMBL4134203 SCHEMBL4134203 0.61 7/20
SCHEMBL4130259 SCHEMBL4130259 0.58 7/20
SCHEMBL4130032 SCHEMBL4130032 1.00 6/20
SCHEMBL12395121 SCHEMBL12395121 1.00 6/20
SCHEMBL12454181 SCHEMBL12454181 0.90 6/20
SCHEMBL12395123 SCHEMBL12395123 0.84 6/20
SCHEMBL12395120 SCHEMBL12395120 0.81 6/20
SCHEMBL12454295 SCHEMBL12454295 0.78 6/20
SCHEMBL12454297 SCHEMBL12454297 0.78 6/20

Clinical trials — most relevant to CDC37 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease PHASE2COMPLETED
STA-9090(Ganetespib) in Metastatic Ocular Melanoma PHASE2COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients PHASE2COMPLETED
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery PHASE1COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies PHASE1WITHDRAWN
AT13387 in Adults With Refractory Solid Tumors PHASE1COMPLETED
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma PHASE1COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors PHASE1COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas PHASE1COMPLETED
STA-9090 in Patients With Advanced Hepatocellular Cancer PHASE1COMPLETED
Q-Trial in Patients With Hepatitis C PHASE1COMPLETED
Study of Curcumin, Vorinostat, and Sorafenib PHASE1WITHDRAWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC37 binder may also engage these)

ProteinNameSimilarity
Q5EAC6 — 1.000 Q5EAC6 →
Q63692 — 1.000 Q63692 →
Q9DGQ7 — 1.000 Q9DGQ7 →
Q61081 — 1.000 Q61081 →
O57476 — 1.000 O57476 →
Q24276 — 0.999 Q24276 →
Q24740 — 0.996 Q24740 →
O02108 — 0.989 O02108 →
E1C760 — 0.988 E1C760 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.988 landscape →
Q8WYH8 — 0.988 Q8WYH8 →
Q93VM9 — 0.988 Q93VM9 →
Q07205 — 0.987 Q07205 →
Q6NWJ4 — 0.987 Q6NWJ4 →
Q9D8Y8 — 0.987 Q9D8Y8 →
Q1RMH9 — 0.987 Q1RMH9 →
Q7SH49 — 0.987 Q7SH49 →
Q96G28 — 0.986 Q96G28 →
Q3ZC62 — 0.986 Q3ZC62 →
B5X171 — 0.986 B5X171 →
Q7TQK5 — 0.986 Q7TQK5 →
Q3TPE9 — 0.986 Q3TPE9 →
P19351 — 0.986 P19351 →
Q99543 — 0.986 Q99543 →
Q8BMP6 — 0.986 Q8BMP6 →
P97496 — 0.986 P97496 →
Q7T0S7 — 0.986 Q7T0S7 →
Q5ZKI4 — 0.985 Q5ZKI4 →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.985 landscape →
F7AEX0 — 0.985 F7AEX0 →